Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Regis999]

Autism inflammation

call 1800-778-2031 extension 4 and talk with Anatabloc doctor


http://tinyurl.com/adwjz89

And that is major news. It seems inflammation in the brain is the underlying mechanism of most if not all chronic CNS disorders: Autism, Down Syndrome, Rett Syndrome and as we will see Alzheimer’s Dementia,and Parkinsonism. It may be the root causes of ADHD and Learning Disorders as well, but this is less certain.


Anatabloc is all about inhibiting the expression of NF-kB (inflammation). Numerous human ailments are caused by chronic low grade inflammation associated with elevated NF-kB levels in the body. Anatabloc is a dietary supplement for anti-inflammatory support of the immune system. Anatabloc turns off that chronic inflammation and therefore could be helpful in everything from MS, Parkinsons (and all auto-immune diseases). , Alzheimers, Diabetes, Thyroid Disease, Heart Disease, autism, Crohns Disease, Fibromyalgia,Rheumatoid Arthritis, Asthma, Allergies, etc. etc.

ANATABLOC attacks inflammation --watch this

Studies are being done now at John Hopkins related to several of these. Watch

Use of Anatabine (Anatabloc at GNC) to treat a Autism and a Seizure Disorder

By real2play.Nov 9, 2012 3:42 PM.Permalink

A 10-year old male patient, who was diagnosed with autism and a seizure disorder, had brain surgery and began rehabilitation the following month. About 4 months later, in addition to continuing rehabilitation, he began a course of treatment with 1 .0 mg of Anatabine three times per day. Over the course of 3 ½ weeks the frequency of the patient's seizures decreased from one per day to approximately one per week. The patient also experienced cognitive benefits beginning approximately one week after the start of the anatabine treatment, with noticeable improvements daily. These benefits included improved communication and language skills and the ability to focus.

'The patient also experienced cognitive benefits beginning approximately one week after the start of the anatabine treatment'


Use of anatabine in a patient with high functioning autism

( 158) Anatabine was used to treat a 12-year old male patient weighing 140 pounds and described as having high functioning autism. The patient is mainstreamed in school and functions well intellectually, but is somewhat emotionally labile (l imbic system dysfunction) and has difficulty coping with stressful and emotional situations. After taking 2 mg of analabine citrate three times a day for three days, the patient experienced an incident in school which in the past would have resulted in acting out, cognitive perseveration, dramatic retellings of the incident and difficulty in expressing his thoughts and feelings. This incident however, was notable for its lack of drama. The patient demonstrated a relaxed demeanor when relating the facts of the incident. He w as able to put it into perspective and "let it go."

http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012149295&recNum=1&office=&queryString=FP%3A%28Anatabine+Rock+Creek%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=4


This makes you wonder how much mental illness is inflammation driven.
Anatabloc for Mental Illness

By riprising.8 minutes ago.Permalink
Friend told me his mother, now 45 has mental illness (despair, breaks down crying, cannot handle life etc.). I told him to give her Anatabloc. After three weeks he says she feels happy and like she is 15 years old. She is planning a vacation to visit family in the San Francisco area which would have been beyond her three weeks ago. Friend says the change in his mother is drastic. I suspect inflammation in the brain is a source of much mental illness..

Research Presented at Neuroscience 2012 Indicates Anatabine Supplementation is Potentially Helpful in Recovery from Traumatic Brain Injury

GLEN ALLEN, Va., Oct. 15, 2012 /PRNewswire/ -- Star Scientific, Inc. (STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc., reports that scientists from its research partner, the Roskamp Institute, presented new research yesterday and today indicating that supplementation with anatabine, the active ingredient in the Company's Anatabloc® dietary supplement, has the potential to alleviate the negative consequences of traumatic brain injury (TBI). These findings were presented during a press conference and also at a nanosymposium presentation at Neuroscience 2012, the 42nd annual meeting of the Society for Neuroscience, attended by more than 32,000 neuroscientists from around the world. Those scientists are gathering in New Orleans, Louisiana, this week to observe and participate in presentations relating to more than 16,000 new discoveries in science and health.

(Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO)

On Sunday morning, Dr. Fiona Crawford, Associate Director and Vice President of the Roskamp Institute, was one of four presenters participating in a press conference titled," 'Invisible' Wounds: From Soldiers to Citizens", which focused on traumatic brain injury research working to improve the lives of citizens and soldiers. In the press conference, Dr. Crawford described the Roskamp Institute's larger traumatic brain injury research program and the Institute's work investigating anatabine's effect in laboratory models of TBI.

On Monday morning, Dr. Scott Ferguson, also of the Roskamp Institute, presented these data in a presentation titled, "TBI-Induced Spatial Memory Loss is Averted by Treatment with the Dietary Supplement Anatabine". In this study, three groups of mice were studied: One group of TBI mice was treated with anatabine, while a second group of TBI mice was untreated. A third group was comprised of normal mice. The results of the study showed that the untreated TBI mice demonstrated memory impairment; whereas, the memory of anatabine treated TBI mice was the same as normal mice. The scientists at the Roskamp Institute hypothesize that the maintenance of normal memory in TBI mice treated with anatabine is due to an inhibition of inflammation. The presentation abstract notes: "Anatabine treatment appeared to completely prevent the loss of spatial memory retention following severe TBI."

Dr. Crawford stated, "Further study of this promising treatment is warranted and will include evaluation in a mild closed head injury model as well as assessment of long term outcome from injury." Dr. Michael Mullan, President and CEO of the Roskamp Institute, explained, "Dietary supplementation to prevent memory loss after head injury has a potentially rapid development path for human use." According to the Centers for Disease Control, 1.7 million people in the United States experience TBI each year, with 80,000 survivors suffering long-term disability.

In addition to the TBI research, the Roskamp Institute presented results of its research examining the potential benefit of anatabine for alleviating symptoms associated with Multiple Sclerosis and will present new research on anatabine's effect on Alzheimer's Disease at the conference. For more information about the TBI study and the MS study, visit the Roskamp Institute's website at: www.rfdn.org